---
title: "Weekly Recap | Merck +2.04%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299512757.md"
description: "Merck (MRK) gained 2.04% over the week to close at $146.87, while the S&P 500 slipped 0.08%, leaving the stock roughly 2.12 percentage points ahead of the benchmark. The pattern was back-end loaded: Monday opened higher but faded, Tuesday marked the intraweek low of $142.32, and the stock then climbed in three straight sessions to reach $147.15 on Thursday before easing slightly on Friday. Weekly amplitude was 3.77%."
datetime: "2026-09-19T06:23:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299512757.md)
  - [en](https://longbridge.com/en/news/299512757.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299512757.md)
generator: "portal-rs"
---

# Weekly Recap | Merck +2.04%, most brokers rate it buy

## The Week

Merck (MRK) gained 2.04% over the week to close at $146.87, while the S&P 500 slipped 0.08%, leaving the stock roughly 2.12 percentage points ahead of the benchmark. The pattern was back-end loaded: Monday opened higher but faded, Tuesday marked the intraweek low of $142.32, and the stock then climbed in three straight sessions to reach $147.15 on Thursday before easing slightly on Friday. Weekly amplitude was 3.77%.

## Key Events

The week centred on Keytruda’s multi-track momentum. Early in the week, Merck and Perspective Therapeutics announced a clinical collaboration to evaluate \[212Pb\] PSV359 with Keytruda in FAP-α positive solid tumours. The CEO later framed new launches and the animal health business as the drivers of pipeline upside. On Friday, Merck received a positive EU CHMP opinion for Keytruda plus Padcev as perioperative treatment for resectable muscle-invasive bladder cancer, and separately launched a whole-person care programme for people living with HIV. On the space-pharma front, Merck is also scouting new facilities for Keytruda space research as the ISS retirement approaches.

## Analyst Ratings

Across 28 covering institutions, 15 rate the stock buy, 5 rate it over, and 8 rate it hold, with no under or sell ratings. The consensus recommendation is buy, and the consensus target of $152.96 sits about 4.15% above the latest close of $146.87. The target range is wide at $105 to $186, indicating meaningful dispersion. Within its industry, Merck ranks 3rd out of 204 names.

## The Week Ahead

No Merck earnings are scheduled next week. Macro releases dominate: Richmond Fed composite index on Tuesday, EIA crude inventories on Wednesday, and initial jobless claims plus new home sales on Thursday. Merck’s next report is the fiscal Q3 2026 result before the open on 29 October, where consensus estimates stand at EPS of $1.90 and revenue of $17.4 billion.

## In Short

Merck paired steady regulatory and clinical headlines with a weekly gain that outpaced the benchmark. The Street consensus stays at buy and the target sits modestly above spot, but the wide target range and a price-to-earnings near 114x reflect divided views on how quickly the pipeline converts to growth. The next checkpoints are whether Keytruda’s new indications and space-research initiatives translate into results, and how the October quarter shapes up against full-year targets.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Key facts: Merck (MRK) up on vaccine; policy may hit M-M-R II, ProQuad](https://longbridge.com/en/news/296749142.md)
- [Braun Stacey Associates Inc. Has $35.07 Million Stock Position in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/297397633.md)
- [Michael Saylor Says, 'A Little More Orange': Will Strategy Report BTC Purchases After Hitting Pause for 3 Weeks?](https://longbridge.com/en/news/299601303.md)
- [Tesla eyes supply partners for Optimus mass production](https://longbridge.com/en/news/299569894.md)
- [Ares Management (ARES) Forms Logistics Venture, Is The Stock A Bargain?](https://longbridge.com/en/news/299564323.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**